Skip to content

Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia

Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia:a Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05431010
Enrollment
120
Registered
2022-06-24
Start date
2022-07-02
Completion date
2026-12-31
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Keywords

sarcopenia;electroacupuncture; geriatric

Brief summary

Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia. Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. Subjects will be randomly assigned in a 1:1 ratio to either EA combined with rehabilitation training group or rehabilitation training group through a central computerized randomization system. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial. Conclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.

Detailed description

Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia. Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. The experimental group is EA combined with rehabilitation training group, while the control group is rehabilitation training group. Rehabilitation training is the more recognized treatment method for sarcopenia all over the world. Eligible subjects will be randomly assigned to two group in a 1:1 allocation ratio. All participants will undergo 12 weeks of treatments in two groups. This protocol is based on the standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) and the SPIRIT reporting guidelines. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength, such as lower extremity skeletal muscle mass、appendicular skeletal muscle mass、calf circumference、knee flexion and extension strength and grip strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial. Conclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.

Interventions

DEVICEelectroacupuncture

Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.

The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia. 1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load. 2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period

Sponsors

The Third Affiliated hospital of Zhejiang Chinese Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

1. 60 years ≤ age ≤ 95 years, male or female; 2. Patients are able to walk and communicate independently, and can complete required rehabilitation training; 3. Patients meet the diagnostic criteria proposed by the Asian Working Group for Sarcopenia(AWGS); 4. Patients volunteer to participate in this study and sign the informed consent.

Exclusion criteria

1. Patients with serious primary diseases of heart, brain, liver, kidney and hematopoietic system; 2. Patients with severe mental illness, cognitive impairment, and disorientation; 3. Patients have trauma and unsuitable for sports; 4. Patients with electronic devices or metal objects implanted in the body; 5. Patients can't complete the required rehabilitation training; 6. Patients cannot receive EA treatment due to any reasons 7. Patients are participating in other drugs, acupuncture and massage trials.

Design outcomes

Primary

MeasureTime frameDescription
6min walk test12 weeksThe 6-min walking test setup is a straight line of 20 meters on a flat floor, and a chair is placed at each end as a sign. The subjects walk back and forth between them. The pace of walking is determined according to their own physical fitness, and they walk as fast as possible. In this way, the maximum walking distance that an individual can reach within 6 minutes will be texted
time to get up and go(TGUG)12 weeksThe TGUG test measures the time it takes for an individual to get up from a chair, complete a short 3 meters round-trip walk, and finally sit back in the chair.
short physical performance battery (SPPB)12 weeksSPPB is a comprehensive test instrument that includes a walking speed test, a sit-to-stand test, and a balance test. The Walking Speed Test measures the time to pass a distance of 4 meters at daily walking speed. Sit-to-stand test is to calculate the time to complete 5 consecutive sets of getting up-sit down. The balance test includes 3 parts: 10 seconds for standing on the left and right side of both feet; standing on half front and half rear feet and standing on front and rear feet

Secondary

MeasureTime frameDescription
lower extremity skeletal muscle mass12 weeksThe skeletal muscle mass of the lower limbs can be detected separately by applying the BCA body composition analyzer produced by Tsinghua Tongfang
appendicular skeletal muscle mass(ASMM)12 weeksThe BCA body composition analyzer produced by Tsinghua Tongfang can be used to directly test the skeletal muscle mass of the extremities.
calf circumference12 weeksMeasured by applying a measuring tape horizontally around the circumference of the thickest part of the calf
knee flexion and extension strength12 weeksThe TB-ISO multi-joint isometric strength testing system (made in Italy) was applied to test the peak moment/peak moment body weight ratio, average power, and total work for the isometric exercise of knee flexion and knee extension, respectively.
grip strength12 weeksgrip strength was obtained by grip strength measurement

Countries

China

Contacts

CONTACTWenzhe Wu, Master
2008777.1378@163.com18757570729
STUDY_DIRECTORWenzhe Wu, Master

The Third Affiliated hospital of Zhejiang Chinese Medical University

PRINCIPAL_INVESTIGATORMing Guo, Doctor

Xiyuan Hospital of China Academy of Chinese Medical Sciences

PRINCIPAL_INVESTIGATORHantong Hu, Doctor

The Third Affiliated hospital of Zhejiang Chinese Medical University

PRINCIPAL_INVESTIGATORHong Gao, Master

The Third Affiliated hospital of Zhejiang Chinese Medical University

PRINCIPAL_INVESTIGATORJinkuo Pang, Bachelor

The Third Affiliated hospital of Zhejiang Chinese Medical University

PRINCIPAL_INVESTIGATORYanfei Cao, Master

The Third Affiliated hospital of Zhejiang Chinese Medical University

PRINCIPAL_INVESTIGATORYiting Zhang, Master

The Third Affiliated hospital of Zhejiang Chinese Medical University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026